Impact of age-, cancer-, and treatment-driven inflammation on T cell function and immunotherapy

J Leukoc Biol. 2020 Sep;108(3):953-965. doi: 10.1002/JLB.5MR0520-466R. Epub 2020 Jul 17.

Abstract

Many cancers are predominantly diagnosed in older individuals and chronic inflammation has a major impact on the overall health and immune function of older cancer patients. Chronic inflammation is a feature of aging, it can accelerate disease in many cancers and it is often exacerbated during conventional treatments for cancer. This review will provide an overview of the factors that lead to increased inflammation in older individuals and/or individuals with cancer, as well as those that result from conventional treatments for cancer, using ovarian cancer (OC) and multiple myeloma (MM) as key examples. We will also consider the impact of chronic inflammation on immune function, with a particular focus on T cells as they are key targets for novel cancer immunotherapies. Overall, this review aims to highlight specific pathways for potential interventions that may be able to mitigate the impact of chronic inflammation in older cancer patients.

Keywords: IL-1; IL-6; TNF; multiple myeloma; ovarian cancer.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aging / immunology*
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Chronic Disease
  • Combined Modality Therapy
  • Cytokines / immunology
  • Disease Susceptibility
  • Female
  • Humans
  • Immunocompetence
  • Immunologic Factors / therapeutic use
  • Immunotherapy* / methods
  • Immunotherapy, Adoptive
  • Inflammation / complications
  • Inflammation / immunology*
  • Inflammation / therapy
  • Lymphocyte Activation
  • Models, Immunological
  • Multiple Myeloma / immunology
  • Multiple Myeloma / therapy
  • Neoplasms / complications
  • Neoplasms / immunology*
  • Ovarian Neoplasms / immunology
  • Ovarian Neoplasms / therapy
  • Proteasome Inhibitors / therapeutic use
  • Receptors, Immunologic / immunology
  • Signal Transduction
  • T-Lymphocytes / immunology*

Substances

  • Cytokines
  • Immunologic Factors
  • Proteasome Inhibitors
  • Receptors, Immunologic